Theravance Biopharma TBPH Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | 1.2%+4.6pp | -3.4%+37.5pp | -40.9%+7.3pp | -48.2%+28.7pp | -76.9%-4.0pp | |
| Net margin | 104.3%+5.8pp | 98.5%+62.0pp | 36.5%+19.7pp | 16.9%+106pp | -89.4%-1.7pp | |
| EBITDA margin | 2.7%+4.5pp | -1.8%+37.0pp | -38.8%+7.2pp | -46%+28.3pp | -74.3%-4.0pp | |
| Returns | ||||||
| Return on equity | 50.2%+5.3pp | 44.8%+30.8pp | 14%+7.8pp | 6.2%+37.7pp | -31.5%-2.4pp | |
| Return on assets | 28.1%+2.9pp | 25.2%+17.6pp | 7.6%+4.3pp | 3.3%+19.6pp | -16.3%-1.0pp | |
| Efficiency | ||||||
| Asset turnover | 0.3×0.0× | 0.3×0.0× | 0.2×0.0× | 0.2×0.0× | 0.2×0.0× | |
| Liquidity | ||||||
| Current ratio | 13.1×+2.2× | 10.9×+1.4× | 9.5×+2.8× | 6.7×+1.9× | 4.8×-0.3× | |
| Quick ratio | 13.1×+2.2× | 10.9×+1.4× | 9.5×+2.8× | 6.7×+1.9× | 4.8×-0.3× | |
| Cash ratio | 9.1×+4.7× | 4.4×-0.3× | 4.7×-0.5× | 5.2×+1.6× | 3.5×+2.3× | |
| Leverage | ||||||
| Debt-to-equity | 0.1×0.0× | 0.1×0.0× | 0.2×0.0× | 0.2×-0.1× | 0.3×0.0× | |
| Debt-to-assets | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | |
| Per Share | ||||||
| Book value per share | $5.67-1.6% | $5.76+28.5% | $4.48+1.1% | $4.43+32.7% | $3.34-7.1% | |
| Valuation | ||||||
| Market capitalization | $896.51M+68.7% | $948.08M+28.9% | $735.27M+37.8% | $533.51M+20.8% | $441.77M-4.5% | |
| Enterprise value | $648.91M+38.3% | $822.98M+36.0% | $605.1M+103% | $298.04M-21.4% | $379.31M-20.1% | |
| Price / earnings | 7.8×— | —— | —— | —— | —— | |
| Price / sales | 8.2×0.0× | 8.8×-0.3× | 9.2×+2.2× | 6.9×+0.1× | 6.8×-0.4× | |
| Price / book | 3.1×-0.1× | 3.2×0.0× | 3.2×+0.8× | 2.4×-0.3× | 2.7×0.0× | |
| EV / sales | 5.9×-1.3× | 7.7×+0.1× | 7.5×+3.7× | 3.9×-2.0× | 5.8×-1.6× | |
| Earnings yield | 12.8%+23.8pp | 11.2%+7.2pp | 4%+1.5pp | 2.4%+15.6pp | -13.2%-1.0pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Theravance Biopharma's profit margins?
- Theravance Biopharma (TBPH) runs a 60.8% gross margin and a 1.2% operating margin, with a 104.3% net margin.
- Where do Theravance Biopharma's ratios come from?
- Every ratio is computed from Theravance Biopharma's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
